Combining lenalidomide with erythropoiesis stimulating agents: a party of one

Leukemia. 2024 Mar;38(3):473-474. doi: 10.1038/s41375-024-02176-z. Epub 2024 Feb 15.

Authors

Namrata S Chandhok¹, Mikkael A Sekeres²

Affiliations

¹ Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
² Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. msekeres@med.miami.edu.

PMID: 38360864
DOI: 10.1038/s41375-024-02176-z

No abstract available

Publication types

Review

MeSH terms

Erythropoiesis
Hematinics* / pharmacology
Hematinics* / therapeutic use
Humans
Lenalidomide / pharmacology
Myelodysplastic Syndromes*
Thalidomide / pharmacology
Thalidomide / therapeutic use

Substances

Lenalidomide
Hematinics
Thalidomide